Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Synta Pharmaceutical (SNTA) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 37,330
  • Shares Outstanding, K 137,810
  • Annual Sales, $ 0 K
  • Annual Income, $ -68,670 K
  • 36-Month Beta 1.06
  • Price/Sales N/A
  • Price/Book 0.90
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.26
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.25 +36.00%
on 07/20/16
0.40 -15.00%
on 07/22/16
+0.03 (+9.68%)
since 06/22/16
3-Month
0.25 +36.00%
on 07/20/16
0.45 -24.44%
on 05/13/16
-0.03 (-8.11%)
since 04/22/16
52-Week
0.15 +126.67%
on 02/08/16
2.23 -84.75%
on 08/11/15
-1.80 (-84.11%)
since 07/22/15

Most Recent Stories

More News
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015

Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their...

Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis

Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This...

Malignant Mesothelioma Therapeutics Pipeline Review, H2 2015

Research and Markets (http://www.researchandmarkets.com/research/2dt2rm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2015" report to their offering. This...

BUYINS.NET: FNGN, SNTA, FIG Are Seasonally Ripe To Go Up In the Next Five Weeks

BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Financial Engines Inc (NASDAQ:FNGN), Synta Pharmaceuticals Corp (NASDAQ:SNTA), Fortress Investment Group LLC (NYSE:FIG) and each have...

4 Small Cap NASDAQ/NYSE Stocks Trading With Heavy Volume

NEW YORK, NY / ACCESSWIRE / December 15, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential....

Global Refractory Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015 - 50 Companies & 117 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/5gtx2j/refractory_acute) has announced the addition of the "Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their...

World Malignant Pleural Mesothelioma Therapeutics Pipeline Report H2 2015 - 32 Companies & 40 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/4n84qr/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H2 2015" report to their...

Relapsed Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015

Research and Markets (http://www.researchandmarkets.com/research/5bkxtd/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their offering. This...

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 with AstraZeneca, Celgene, Eli Lilly, F. Hoffmann-La Roche & Pfizer Dominating

Research and Markets (http://www.researchandmarkets.com/research/4z56z7/global_nonsmall) has announced the addition of the "Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019" report to their...

Synta Reports Third Quarter 2015 Financial Results

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its business strategy.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

SYNTA PHARMACEUTICALS CORP. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound...

See More

Support & Resistance

2nd Resistance Point 0.47
1st Resistance Point 0.40
Last Price 0.34
1st Support Level 0.27
2nd Support Level 0.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.